See other companies on Welcome to the Jungle
INBRAIN Neuroelectronics
Neural interfaces for brain restoration
- 21-100 employees
- Healthcare
- Enterprise
- MedTech
- Dreta de l'Eixample, Barcelona, CT
Jump to section
Company mission
To build neuroelectronic interfaces to cure brain disorders.
26% employee growth in 12 months
Our take
More than 35% of the population have been afflicted with brain disorders, costing around €800 billion per year in each of Europe and the USA. The drugs to treat those disorders make up around 20% of this, with patients suffering from additional side effects. Currently all brain interfaces are metal based, which are met with restrictions that limit therapeutic effect.
INBRAIN Neuroelectronic's bioelectrical implants technology uses the power of graphene, which has a unique blend of electrical and thermal conduction properties. Combined with machine learning software that delivers an adaptive neuromodulation therapy personalised for each patient, INBRAIN believe that this could be a faster and safer way of brain restoration, free of side effects.
INBRAIN Neuroelectronics have recently secured substantial funding which will be used to drive their first in-human clinical program. They aim to demonstrate the safety of graphene as the new standard of care for neurotechnology devices, which could be a revolutionary development for the industry.
Kirsty
Company Specialist at Welcome to the Jungle
Benefits
- An opportunity to revolutionize neuroelectronic therapies and work within one of the most dynamic, multi-disciplinary and experienced start-ups in Europe.
- A fun but balanced organization with flexible work & vacation policy.
- Growth potential. We expect rapid advancement of team members who have an outsized impact.
- A potential stock option plan.
Funding (last 2 of 6 rounds)
Oct 2024
$48.7m
SERIES B
Oct 2023
$3.2m
CONVERTIBLE
Total funding: $72m
Leadership
Carolina Aguilar
(CEO)Formerly a Business Director and Manager for Medtronic.